Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.49 |
| ▸ | TUBB | P07437 | 1/20 | 0.49 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.49 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.49 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.49 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.49 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.49 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.49 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.49 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.49 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.49 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.49 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.49 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.49 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27008293 | 0.83 | CTSV (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL27142999 | 0.78 | CTSV (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL31451597 | 0.76 | TUBB4A (0.64) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL31740138 | 0.76 | TUBB4A (0.64) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL27027505 | 0.75 | GPR17 (0.53) | MAPTALDH1A1KDM4EGAANPSR1 | |
| SCHEMBL29032428 | 0.75 | MAOB (0.58) | MAPTHPGDLMNATSHRMAOA | |
| SCHEMBL25686475 | 0.74 | MAPT (0.75) | MAPTALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL29032416 | 0.73 | RAB9A (0.48) | MAPTALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL5195111 | 0.73 | ALDH1A1 (0.54) | MAPTALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL26426649 | 0.73 | KAT6A (0.48) | MAPTHPGDLMNAFLT3KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197409-A1 | BIFUNCTIONAL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE BIFUNCTIONAL COMPOUND, AND METHOD FOR TREATING ANDROGEN RECEPTOR RELATED DISEASE BY USING THE SAME | ANHORN MEDICINES CO., LTD. (TW) | 2025-06-19 | — | — | US | disclosed |
| EP-4547667-A1 | BIFUNCTIONAL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE BIFUNCTIONAL COMPOUND, AND METHOD FOR TREATING ANDROGEN RECEPTOR RELATED DISEASES BY USING THE SAME | Anhorn Medicines Co., Ltd. (TW) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024002206-A1 | BIFUNCTIONAL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE BIFUNCTIONAL COMPOUND, AND METHOD FOR TREATING ANDROGEN RECEPTOR RELATED DISEASES BY USING THE SAME | ANHORN MEDICINES CO., LTD. (CN) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197409-A1 | BIFUNCTIONAL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE BIFUNCTIONAL COMPOUND, AND METHOD FOR TREATING ANDROGEN RECEPTOR RELATED DISEASE BY USING THE SAME | ADRM1, AR, UBE2L3 | TUBB4A 2368/4885TUBB 2102/4885TUBA3C 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.